spacer
home > directory > Dynascan
PHARMACEUTICAL INDUSTRY DIRECTORY

Dynascan

Dynascan
Company profile Dynascan is a world-leading manufacturer of innovative seal integrity and leak detection solutions. Founded in 2001 by a highly skilled team of specialists, more than 30 years of experience has been input into the development of the Dynascan product range. All test systems are designed and manufactured to ISO standards.

Dynascan is essential leak detection equipment for any packaging facility offering a wide range of packaging seal integrity and leak detection solutions to suit most food, pharmaceutical, medical and industrial applications.

Testing methods vary from burst testing and bubble emissions to pressure decay, reactive force, altitude simulation and blue dye.

All test systems are designed and manufactured to the highest quality, with an individual, tailor-made bespoke service available, providing complete technical and engineering solutions.

To find out more information about our testing services and products, please contact us on +44 (0)1480 462142. Alternatively, you can email info@dynascan.co.uk or visit www.dynascan.co.uk for further information.

Based in the UK, Dynascan is a brand of Cambridge Sensotec, experts in gas analysis.
phone +44 (0)1480 462142
email info@dynascan.co.uk
web www.dynascan.co.uk
email 29 Stephenson Road, St Ives, Cambridgeshire PE27 3WJ
 
spacer

Member login

E-mail address:

Password:
Remember me

Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 
News and Press Releases

Avacta develops SARS-COV-2 neutralising Affimer reagents with therapeutic potential for COVID-19

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that several of the Affimer reagents recently generated for development of a point-of-care COVID-19 antigen saliva test have now also been shown to block the interaction between the virus’ spike protein and ACE2, a receptor on human cells that is key to the virus infection pathway1.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement